[Immunohistochemistry and personalised medicine in lung oncology: advantages and limitations].
The concept of personalized or stratified medicine in thoracic oncology have led to the development of companion diagnostic testing in the laboratories in order to detect genomic alterations which can be targeted by therapeutic molecules. The use of these companion tests has to be associated with an optimized quality control with the aim of getting solid results before treatment administration to the patients. The great majority of these tests is based on molecular biology approach. However, since the commercial availability of different antibodies targeting genomic alterations which can be used in formalin fixed paraffin sections, an alternative method to the molecular approach is the immunohistochemistry (IHC). Some of these antibodies are or will be probably soon used in a daily routine practice (such as anti-ALK or anti-MET antibodies). Other antibodies have currently a more restricted use in thoracic oncology (such as anti-BRAF V600E, anti-ROS1 and mutation-specific anti-EGFR antibodies). In this review, we aim to detail the advantages and the limits of IHC method in thoracic oncology field for personalized medicine, in particular comparatively to the molecular biology technology. Moreover, we discuss the opportunity to provide accredited IHC tests in the context of stratified medicine for lung cancer patients.
Hôpital Pasteur, Centre Hospitalo-universitaire, Université de Nice Sophia-Antipolis, Laboratoire de pathologie clinique et expérimentale et biobanque du CHUN, Laboratoire de pathologie clinique et expérimentale, 30, avenue de la Voie-romaine, 06001 Nice cedex 01, France.
Véronique
V
Hofman
Hôpital Pasteur, Centre Hospitalo-universitaire, Université de Nice Sophia-Antipolis, Laboratoire de pathologie clinique et expérimentale et biobanque du CHUN, Laboratoire de pathologie clinique et expérimentale, 30, avenue de la Voie-romaine, 06001 Nice cedex 01, France.
Marius
M
Ilie
Hôpital Pasteur, Centre Hospitalo-universitaire, Université de Nice Sophia-Antipolis, Laboratoire de pathologie clinique et expérimentale et biobanque du CHUN, Laboratoire de pathologie clinique et expérimentale, 30, avenue de la Voie-romaine, 06001 Nice cedex 01, France.
Elodie
E
Long
Hôpital Pasteur, Centre Hospitalo-universitaire, Université de Nice Sophia-Antipolis, Laboratoire de pathologie clinique et expérimentale et biobanque du CHUN, Laboratoire de pathologie clinique et expérimentale, 30, avenue de la Voie-romaine, 06001 Nice cedex 01, France.
Sandra
S
Lassalle
Hôpital Pasteur, Centre Hospitalo-universitaire, Université de Nice Sophia-Antipolis, Laboratoire de pathologie clinique et expérimentale et biobanque du CHUN, Laboratoire de pathologie clinique et expérimentale, 30, avenue de la Voie-romaine, 06001 Nice cedex 01, France.
Catherine
C
Butori
Hôpital Pasteur, Centre Hospitalo-universitaire, Université de Nice Sophia-Antipolis, Laboratoire de pathologie clinique et expérimentale et biobanque du CHUN, Laboratoire de pathologie clinique et expérimentale, 30, avenue de la Voie-romaine, 06001 Nice cedex 01, France.
Coraline
C
Bence
Hôpital Pasteur, Centre Hospitalo-universitaire, Université de Nice Sophia-Antipolis, Laboratoire de pathologie clinique et expérimentale et biobanque du CHUN, Laboratoire de pathologie clinique et expérimentale, 30, avenue de la Voie-romaine, 06001 Nice cedex 01, France.
Kevin
K
Washetine
Hôpital Pasteur, Centre Hospitalo-universitaire, Université de Nice Sophia-Antipolis, Laboratoire de pathologie clinique et expérimentale et biobanque du CHUN, Laboratoire de pathologie clinique et expérimentale, 30, avenue de la Voie-romaine, 06001 Nice cedex 01, France.
Salomé
S
Lalvee
Hôpital Pasteur, Centre Hospitalo-universitaire, Université de Nice Sophia-Antipolis, Laboratoire de pathologie clinique et expérimentale et biobanque du CHUN, Laboratoire de pathologie clinique et expérimentale, 30, avenue de la Voie-romaine, 06001 Nice cedex 01, France.
Paul
P
Hofman
D000906:Antibodies; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008175:Lung Neoplasms / Q000235:genetics* / Q000628:therapy*; D058990:Molecular Targeted Therapy / Q000379:methods*; D009154:Mutation; D057285:Precision Medicine / Q000379:methods*
D000906:Antibodies
accreditation; immunohistochemistry; lung cancer; molecular biology; personalized medicine; targeted therapy